April 2019 Journal Review Roundup

April 2019 Primary Care Sports Medicine Journal Roundup

The American Journal of Sports Medicine (April 2019)

  • The risk of prolonged opioid use after arthroscopic shoulder procedures is 8.3%, and it is higher among women and among those with greater opioid use in the early postoperative period, mental health conditions, substance dependence and abuse, and preexisting pain disorders

  • Nonoperatively treated (85%) and operatively treated (72%) athletes successfully returned to the same sport without injury for at least 1 full season (P = .11).

  • Players sustaining a dislocation were significantly more likely to fail to return when compared with those sustaining a subluxation (26% vs 89%, P = .013).

  • Among patients with chronic gluteal tendinopathy and a length of symptoms >15 months, a single intratendinous LR-PRP injection performed under ultrasound guidance results in greater improvement in pain and function than a single CSI.

  • The improvement after LR-PRP injection is sustained at 2 years, whereas the improvement from a CSI is maximal at 6 weeks and not maintained beyond 24 weeks.

British Journal of Sports Medicine (April Volume 7, April Volume 8)

  • The CES-D score indicated mild to moderate symptoms of depression in 48 (16.6%) and severe symptoms in 41 (14.1%) players

  • The GAD-7 score indicated an at least moderate generalised anxiety disorder in 24 (8.3%) players

  • Only a third of the 45 (15.7%) players who stated that they currently wanted or needed psychotherapeutic support received it!!

  • Physical activity declines modestly between adolescence and young adulthood

  • Athletes were often unable to achieve sleep recommendations during training or competition periods.

  • Sleep was impaired the night of competition compared with previous nights.

  • Early morning training, increases in training load, travel departure times, jet lag and altitude can impair athletes’ sleep

Sports Medicine (April 2019)

  • Only 5 of 23 substance classes show evidence of having the ability to enhance actual sports performance, i.e. anabolic agents, β2-agonists, stimulants, glucocorticoids and β-blockers.

  • One additional class, growth hormone, has similar evidence but only in untrained subjects.

  • The observed effects all relate to strength or sprint performance (and accuracy for β-blockers); there are no studies showing positive effects on reliable markers of endurance performance.

  • For 11 classes, no well-designed studies are available, and, for the remaining six classes, there is evidence of an absence of a positive effect.

  • VAD attributed to sports participation is uncommonly reported and the mechanisms are varied.

  • Impact to the mastoid region is consistently implicated in fatal cases and should be the focus of injury prevention strategies in sport.

  • There are currently no published evidence-based criteria to inform RTS decisions for patients with an LAS injury.

Sports Health Journal